Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: An exploratory analysis of AVAglio

Neuro-Oncology

Volumn 18, Issue 9, 2016, Pages 1313-1318

  Chinot, Olivier L ^a   Nishikawa, Ryo ^b   Mason, Warren ^c   Henriksson, Roger ^d,e   Saran, Frank ^f   Cloughesy, Timothy ^g   Garcia, Josep ^h   Revil, Cedric ^h   Abrey, Lauren ^h   Wick, Wolfgang ⁱ  

^a AIX MARSEILLE UNIVERSITY   (France)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Regional Cancer Center Stockholm and Gotland   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

bevacizumab; crossover; glioblastoma; newly diagnosed; overall survival

Indexed keywords

BEVACIZUMAB; PLACEBO; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BRAIN NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84986000580     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now046     Document Type: Article

References (9)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
2. Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. Neuro Oncol. 2013;15(6):797-805.
3. Chen JY, Hovey E, Rosenthal M, et al. Neuro-oncology practices in Australia: a Cooperative Group for Neuro-Oncology patterns of care study. Asia Pac J Clin Oncol. 2014;10(2):162-167.
4. Scoccianti S, Detti B, Cipressi S, et al. Changes in neurocognitive functioning and quality of life in adult patients with brain tumors treated with radiotherapy. J Neurooncol. 2012;108(2):291-308.
5. Hartmann C, Hentschel B, Simon M, et al. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res. 2013;19(18):5146-5157.
6. Wick W, Hentschel B, Gramatzki D, et al. Risk factor analysis for patients with newly diagnosed glioblastoma who did not receive salvage therapy. Neuro Oncol. 2014;16(suppl 5):v30.
7. Chinot OL, WickW, MasonW, et al. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
8. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
9. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157-173.